Type of non Hodgkin's lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...

Read More

Which patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?

Which patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?

Posted by on Jun 7, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of CAR-T treatment for patients with diffuse large B cell lymphoma (DLBCL). The authors found that while a significant number of all patients benefitted from the treatment, some patients were more likely to benefit from it than others. Some background During initial treatment for DLBCL,...

Read More

Which chemotherapy combination causes less kidney damage to patients with non-Hodgkin lymphoma?

Posted by on May 9, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...

Read More

How common are side effects of the heart in patients with non-Hodgkin lymphoma who receive CHOP or R-CHOP chemotherapy?

Posted by on Apr 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how common side effects of the heart, including heart failure, were among patients with non-Hodgkin lymphoma who received CHOP or R-CHOP chemotherapy. The results showed that only a minority developed side effects and that older patients and female patients were more likely to develop them. Some background Both...

Read More

Evaluating pembrolizumab plus R-CHOP chemotherapy for patients with untreated diffuse large B-cell lymphoma

Posted by on Mar 10, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that pembrolizumab can be safely added to R-CHOP, with improved survival outcomes. Some...

Read More

Evaluating mental performance in older survivors of non-Hodgkin lymphoma

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated mental functioning in older survivors of non-Hodgkin lymphoma (NHL). This study concluded that these individuals may have some mental function decline and lower mental function compared to individuals who did not have cancer. Some background Research suggests that cancer treatments have been shown to cause...

Read More

Comparing different sources for stem cell transplantation for patients with lymphoma

Posted by on Feb 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of patients with lymphoma who had an allogeneic stem cell transplant with different sources of stem cells. This study found that stem cells from a matching donor had better outcomes compared to those from unrelated cord blood. Some background Allogeneic stem cell transplantation is one type of stem cell...

Read More

Evaluating high-dose methotrexate plus chemotherapy for patients with diffuse large B-cell lymphoma

Posted by on Feb 16, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of treatment with high-dose methotrexate (Trexall) plus chemotherapy for diffuse B-cell lymphoma (DLBCL). This study concluded that this regimen was promising, with manageable side effects for these patients. Some background DLBCL is the most common type of non-Hodgkin’s lymphoma. Initial treatment...

Read More

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More

Trends in outcomes of allogeneic transplantation for elderly patients with non-Hodgkin lymphoma

Posted by on Dec 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...

Read More

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

Posted by on Nov 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...

Read More